FOSL just handed investors one of the more disorienting setups of the week: a Q1 print that cleared every bar — and a stock that dropped anyway.
Q1 adj. EPS came in at $(0.03), far ahead of the $(0.35) consensus. Sales of $224.8M beat the $204.7M estimate by nearly 10%. The company reaffirmed full-year 2026 revenue guidance of $943.8M–$963.8M, bracketing the Street's $948.6M estimate almost exactly. By most measures, this was a clean report. Yet FOSL closed Tuesday at $3.95, down 11.2% on the day and 23% lower than a month ago. The stock is now well below the $5.40 level at which three insiders sold in mid-April — a price that already looked cheap at the time.
The positioning picture is where things get interesting. Short interest has been creeping up all month, reaching 6.6% of free float — modest in absolute terms but at its highest level since early April. What makes it notable is that the borrow market is barely registering the pressure: cost to borrow is running at just 0.61% annualised, and availability remains relatively loose, suggesting shorts are not fighting over scarce inventory. The clearest signal of the week came in options: the put/call ratio jumped to 0.165 on Tuesday, more than three standard deviations above its 20-day mean of 0.063. That's a statistically extreme defensive posture — the most hedged the options market has been for this name in weeks. Traders appeared to be buying puts into the earnings print, and Tuesday's selloff validated that positioning.
The insider activity in April added another layer of complexity. Three C-suite insiders — CFO Randy Greben, Chief Commercial Officer Joseph Martin, and Chief Level Officer Melissa Lowenkron — each sold shares on April 15 at $5.40. The CFO's sale was the most material at $182,893, representing 0.003% of the company. These were not large transactions in absolute dollar terms, and all three received stock awards in March, so the sales partly reflect routine liquidity. But the timing, coming less than four weeks before a significant earnings beat, is worth noting. Separately, an independent director bought $102,628 worth of stock at $4.68 in mid-March, so the insider signal is mixed rather than clearly negative. Net insider activity over 90 days remains positive at roughly $466K in aggregate value.
Street coverage of FOSL is thin and largely dated. The only actionable recent data point is Maxim Group's Thomas Forte, who raised his target from $5.00 to $7.00 and maintained a Buy rating in mid-March — in response to a prior earnings beat, not the one that just occurred. That $7.00 target still sits well above the current $3.95 print, implying meaningful paper upside, but Fossil carries essentially no analyst consensus beyond that single Buy. Older notes from Wells Fargo (Underweight) and Keybanc date to 2019–2020 and should not be treated as live views. The ORTEX short score of 59.9, while elevated, has actually ticked down slightly from its recent peak above 60. The short score percentile rank of 9 out of 100 confirms bears are present but not at an extreme.
Peer context sharpens the picture. RL fell 6.4% on the week and CPRI dropped 6.8% — so sector headwinds are real. But FOSL's 8.4% weekly decline outpaced both, and its one-month loss of 23% is steeper than anything among its closer comparables. The prior Q1 earnings history is also instructive: the March 2026 print (for Q4 2025) sparked a 19% one-day gain before the stock gave back much of that move over the subsequent five days. The May 2026 print has tracked roughly inverse so far, with sellers arriving rather than buyers.
What to watch now is whether the Q1 beat and reiterated guidance can arrest the slide once the post-earnings-day flush settles — and whether Maxim or any other firm moves its target higher in the coming days to close the gap between the $7.00 estimate and a stock that printed below $4.
See the live data behind this article on ORTEX.
Open FOSL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.